Ray, Arghya
Song, Yan
Du, Ting
Chauhan, Dharminder
Anderson, Kenneth C.
Article History
Received: 4 November 2019
Revised: 7 January 2020
Accepted: 20 January 2020
First Online: 5 February 2020
Change Date: 7 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-021-01996-y
Compliance with ethical standards
:
: K.C.A. is on Advisory board of Celgene, Millenium-Takeda, Gilead, Janssen, and Bristol Myers Squibb, and is a Scientific Founder with financial interest in Acetylon, Oncopep and C4 Therapeutics. D.C. is consultant to Stemline Therapeutic, Inc., Oncopeptides AB; and Equity owner in C4 Therapeutics. The remaining authors declare no conflict of interest.